AbbVie (ABBV) to Release Quarterly Earnings on Wednesday

AbbVie (NYSE:ABBV) is projected to post its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect AbbVie to post earnings of $3.37 per share and revenue of $16.3913 billion for the quarter. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 9:00 AM ET.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the business posted $3.00 EPS. AbbVie’s revenue was up 9.1% on a year-over-year basis. On average, analysts expect AbbVie to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $223.92 on Wednesday. The stock’s 50 day moving average price is $225.14 and its 200 day moving average price is $218.00. The stock has a market cap of $395.75 billion, a price-to-earnings ratio of 169.64, a PEG ratio of 0.91 and a beta of 0.36. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 524.24%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck billion‑dollar licensing deals with Novartis for oncology and Alzheimer’s programs, which expand near‑ and long‑term revenue optionality and signal external validation of AbbVie’s R&D. AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments
• Positive Sentiment: Berenberg raised its price target (to $275) and remains bullish on Skyrizi and Rinvoq momentum, a supportive analyst view that can boost investor sentiment. Berenberg Grows More Confident in AbbVie on Skyrizi and Rinvoq Momentum
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector delivering risankizumab, which could improve dosing convenience and broaden uptake for indications served by Skyrizi. This is a pipeline/utility win. AbbVie Advances Risankizumab Delivery With On‑Body Injector Study Completion
• Positive Sentiment: Small institutional buying reported (Belpointe Asset Management increased its stake), a modest signal of shareholder confidence. Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV
• Neutral Sentiment: Options and retail interest are elevated (coverage from Zacks on options flow and trending status); this can increase volatility but isn’t a fundamental catalyst by itself. Is the Options Market Predicting a Spike in AbbVie Stock?
• Neutral Sentiment: Corporate social impact news (AbbVie Foundation accelerator) and dividend‑king listings support the long‑term income story but are not immediate earnings drivers. The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: The U.S. Medicare Drug Price Negotiation Program named several AbbVie drugs for its next negotiation cycle, including Part B products — a direct pricing risk that could pressure future revenues if negotiated prices are reduced. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: A competitor (Corcept) reported robust Phase III efficacy for an ovarian cancer drug, which could threaten market share in oncology areas where AbbVie competes. Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
• Negative Sentiment: Citigroup trimmed its price target to $230 and assigned a neutral rating, a modest analyst headwind that may cap upside near‑term. Citigroup Lowers Price Target on AbbVie

Analyst Ratings Changes

A number of research firms have recently weighed in on ABBV. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a report on Monday, November 3rd. HSBC raised AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, Berenberg Bank set a $275.00 price target on shares of AbbVie in a report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $247.84.

Institutional Trading of AbbVie

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Amundi boosted its stake in AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after buying an additional 1,414,621 shares during the period. Raymond James Financial Inc. lifted its holdings in shares of AbbVie by 2.4% during the 3rd quarter. Raymond James Financial Inc. now owns 9,557,701 shares of the company’s stock worth $2,212,110,000 after acquiring an additional 220,221 shares during the last quarter. California State Teachers Retirement System boosted its stake in AbbVie by 0.3% in the third quarter. California State Teachers Retirement System now owns 2,792,331 shares of the company’s stock worth $646,536,000 after buying an additional 9,354 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its stake in AbbVie by 3.9% in the second quarter. Corient Private Wealth LLC now owns 2,380,205 shares of the company’s stock worth $442,528,000 after purchasing an additional 90,160 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.